Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SEED Therapeutics
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
June 2, 2026
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
May 23, 2026
SEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156
April 22, 2026
SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
March 30, 2026